🇺🇸 FDA
Patent

US 8575312

Compositions and methods of use for MGD-CSF in disease treatment

granted A61KA61K38/00A61P

Quick answer

US patent 8575312 (Compositions and methods of use for MGD-CSF in disease treatment) held by Five Prime Therapeutics, Inc. expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Five Prime Therapeutics, Inc.
Grant date
Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K38/00, A61P, A61P1/04, A61P1/14